OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
Meta Stock Jumps as AI Cloud Expansion Challenges AWS, Microsoft, and Google 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
South Korea's bio-industry increased its value output by 16.2 percent to 12.32 trillion won in 2019 from 10.48 trillion won the previous year due to robust growth of the outsourced business.
According to data from the Korea Biotechnology Industry Organization, the value of outsourced services that include contract research organization (CRO) and contract manufacturing organization (CMO) businesses jumped 21.1 percent on-year.
South Korea's exports of bioproducts, which rose 28.1 percent on-year to 6.71 trillion won in 2019, largely contributed to the value output.
The exports consisted of biomedicine products accounting for 39 percent, followed by bio-related food at 35.8 percent, and bio services at 12.2 percent.
The exports of cytokine products, including biosimilars, surged 50.7 percent on-year in 2019.
